Zai Lab Limited (HKG:9688)
14.55
+0.23 (1.61%)
May 28, 2026, 9:30 AM HKT
Zai Lab Employees
Zai Lab had 1,784 employees as of December 31, 2025. The number of employees decreased by 85 or -4.55% compared to the previous year.
Employees
1,784
Change (1Y)
-85
Growth (1Y)
-4.55%
Revenue / Employee
1.99M HKD
Profits / Employee
-782.75K HKD
Market Cap
16.45B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1,784 | -85 | -4.55% | 1,784 | 0 |
| Dec 31, 2024 | 1,869 | -306 | -14.07% | 1,869 | 0 |
| Dec 31, 2023 | 2,175 | 139 | 6.83% | 2,175 | 0 |
| Dec 31, 2022 | 2,036 | 85 | 4.36% | 2,036 | 0 |
| Dec 31, 2021 | 1,951 | 757 | 63.40% | 1,951 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Keymed Biosciences | 1,625 |
| InnoCare Pharma | 1,176 |
| Everest Medicines | 812 |
| Ascentage Pharma Group International | 605 |
| CARsgen Therapeutics Holdings | 355 |
| Duality Biotherapeutics | 231 |
| Ascletis Pharma | 202 |
| CStone Pharmaceuticals | 136 |
Zai Lab News
- 5 days ago - Zai Lab (ZLAB) Announces Leadership Change Amid Strategic Developments - GuruFocus
- 6 days ago - Zai Lab announces departure of COO Josh Smiley - TheFly
- 6 days ago - Zai Lab Announces Changes to Senior Leadership Team - Business Wire
- 11 days ago - Insider Sell Alert: Edmondson Frazor Titus III Sells Shares of Zai Lab Ltd (ZLAB) - GuruFocus
- 16 days ago - Zai Lab (ZLAB) Achieves Fast Track Status for New Cancer Treatment - GuruFocus
- 16 days ago - Zai Lab receives FDA Fast Track Designation for zocilurtatug pelitecan - TheFly
- 16 days ago - Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) - Business Wire
- 18 days ago - Zai Lab Q1 Earnings Call Highlights - MarketBeat